Casgevy sales reach $76M in Q2 2026, up 151% on a year earlier; approved in 39 countries

CRISPR Therapeutics/Casgevy (exa-cel)

Vertex booked $76M of Casgevy revenue in the second quarter of 2026, up 78% on the previous quarter and 151% on a year earlier, helped by more infusions outside the US. The therapy is now approved in 39 countries, and Vertex is working on gentler bone-marrow preparation that could widen who can get it.